Deutsche Bank AG boosted its stake in shares of Teleflex Incorporated (NYSE:TFX) by 27.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 112,849 shares of the medical technology company’s stock after buying an additional 24,008 shares during the period. Deutsche Bank AG owned 0.25% of Teleflex worth $28,075,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Comerica Bank boosted its stake in Teleflex by 0.6% during the fourth quarter. Comerica Bank now owns 35,546 shares of the medical technology company’s stock worth $9,778,000 after buying an additional 198 shares during the last quarter. Chartwell Investment Partners LLC boosted its stake in Teleflex by 3.9% during the third quarter. Chartwell Investment Partners LLC now owns 5,444 shares of the medical technology company’s stock worth $1,317,000 after buying an additional 204 shares during the last quarter. Creative Planning boosted its stake in Teleflex by 6.0% during the fourth quarter. Creative Planning now owns 4,119 shares of the medical technology company’s stock worth $1,025,000 after buying an additional 234 shares during the last quarter. Osterweis Capital Management Inc. boosted its stake in Teleflex by 0.3% during the fourth quarter. Osterweis Capital Management Inc. now owns 90,707 shares of the medical technology company’s stock worth $22,570,000 after buying an additional 242 shares during the last quarter. Finally, Barometer Capital Management Inc. raised its position in Teleflex by 3.2% in the fourth quarter. Barometer Capital Management Inc. now owns 8,075 shares of the medical technology company’s stock valued at $2,009,000 after purchasing an additional 250 shares during the period. 90.75% of the stock is currently owned by institutional investors.
Shares of Teleflex Incorporated (NYSE TFX) opened at $262.14 on Tuesday. Teleflex Incorporated has a 1 year low of $191.04 and a 1 year high of $288.78. The company has a quick ratio of 1.51, a current ratio of 2.33 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $11,927.25, a price-to-earnings ratio of 80.17, a price-to-earnings-growth ratio of 1.96 and a beta of 1.22.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $0.04. The firm had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.13 EPS. equities research analysts expect that Teleflex Incorporated will post 9.67 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 15th. Investors of record on Friday, March 2nd were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, March 1st. This represents a $1.36 annualized dividend and a dividend yield of 0.52%. Teleflex’s dividend payout ratio is presently 41.59%.
A number of research firms have commented on TFX. Leerink Swann restated a “buy” rating and issued a $321.00 target price (up previously from $307.00) on shares of Teleflex in a research report on Tuesday, January 30th. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Stephens restated a “buy” rating and issued a $300.00 target price on shares of Teleflex in a research report on Thursday, January 18th. Finally, TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $281.56.
In related news, VP John Deren sold 1,359 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $255.67, for a total value of $347,455.53. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director George Babich, Jr. sold 2,500 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total value of $658,450.00. Following the completion of the sale, the director now owns 10,583 shares in the company, valued at approximately $2,787,350.54. The disclosure for this sale can be found here. Insiders sold a total of 14,259 shares of company stock worth $3,760,536 in the last quarter. Company insiders own 2.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Deutsche Bank AG Buys 24,008 Shares of Teleflex Incorporated (TFX)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/20/deutsche-bank-ag-buys-24008-shares-of-teleflex-incorporated-tfx.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.